|XIGEN S.A. Patent applications|
|Patent application number||Title||Published|
|20130172530||Novel JNK Inhibitor Molecules - The present invention relates to novel JNK inhibitor molecules. The present invention furthermore relates to methods for raising antibodies against such JNK inhibitor molecules as well as to the respective antibodies and cells producing said antibodies.||07-04-2013|
|20120142584||NOVEL TRANSPORTER CONSTRUCTS AND TRANSPORTER CARGO CONJUGATE MOLECULES - The present invention relates to novel transporter constructs of the generic formula (I) D||06-07-2012|
|20120058137||EFFICIENT TRANSPORT INTO WHITE BLOOD CELLS - The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof.||03-08-2012|
|20080274956||Fusion Protein Comprising a Bh3-Domain of a Bh3-Only Protein - This invention relates to a fusion protein comprising at least one first portion (I) comprising a trafficking sequence and at least one second portion (II) comprising a full-length or partial BH3-domain sequence of a BH3-only protein, said fusion protein comprising D-enantiomeric amino acids in retro-inverso order in its portion (I). Furthermore, the invention relates to pharmaceutical compositions containing said fusion protein as well as to the use of said fusion protein.||11-06-2008|
Patent applications by XIGEN S.A.